基于生物信息学和网络药理学探讨紫草有效成分β,β-二甲基丙烯酰阿卡宁抗结直肠癌作用机制OA
Investigation on the function mechanism of the anti-colorectal cancer effect of the active ingredient β,β-dimethylacryloyl alkannin in Arnebiae Radix based on bioinformatics and network pharmacology
目的 采用基因表达数据库(GEO)、网络药理学和分子对接探讨紫草有效成分β,β-二甲基丙烯酰阿卡宁(DMAS)抗结直肠癌(CRC)作用机制.方法 利用瑞士医疗器械数据库(SwissTargetPrediction)、药效团匹配与潜在识别靶标平台(Pharmmapper)、人类基因组数据库(GeneCards)、化合物靶点预测数据库(TargetNet)查找DMAS相关作用靶点.利用GEO数据库和加权基因共表达网络分析(WGCNA)进行临床相关基因分析,将两者结果连同GeneCards数据库CRC检索结果取交集.通过利用蛋白互作网络分析数据库(STRING)和Cytoscape软件,创建蛋白质-蛋白质相互作用(PPI)网络,并使用Centiscape插件筛选出关键核心靶点.为进一步验证这些核心靶点的可靠性,使用受试者工作特征(ROC)曲线进行分析并导入Metascape数据库进行京都基因与基因组百科全书(KEGG)通路和基因本体论(GO)功能富集分析.最后采用AutoDockTools和Pymol软件将DMAS与核心靶蛋白进行分子对接验证和可视化.结果 通过数据库共获得355个DMAS目标,WGCNA共获得5200个CRC临床模块基因,结合GeneCards数据库,共获得99个DMAS和CRC交叉靶点.PPI网络分析筛选出 15个核心靶点,并通过ROC曲线分析确定丝氨酸/苏氨酸激酶(AKT1)、蛋白质P53(TP53)、β-连环蛋白(CTNNB1)、90 kDa热休克蛋白αB1(HSP90AB1)、胰岛素样生长因子1(IGF1)、酪氨酸激酶受体2(ERBB2)、蛋白酪氨酸磷酸酶基因(PTEN)、细胞周期蛋白依赖性激酶2(CDK2)、鼠类肉瘤病毒癌基因(KRAS)、胃蛋白酶原(PGR)、过氧化物酶体增生激活受体γ(PPARG)、基因编码蛋白(SMAD4)、细胞周期调节蛋白激酶4(CDK4)、原癌基因PIK3CA、半胱氨酸天冬氨酸蛋白酶(CASP9)为DMAS调控CRC的关键靶点,并对其进行的KEGG和GO富集分析,显示这些靶点主要集中在磷脂酰肌醇3-激酶-蛋白激酶B(PI3K-Akt)信号通路上.分子对接结果进一步表明,DMAS能够与15个关键靶点有效结合,形成稳定的蛋白质-配体复合物.结论 本研究不仅揭示DMAS抗CRC的关键靶点和分子机制,还为未来深入探索DMAS抗CRC的药理机制提供坚实的理论基础.
Objective To investigate the function mechanism of anti-colorectal cancer(CRC)effect of the active ingredient β,β-dimethylacryloyl alkannin(DMAS)in Arnebiae Radix using gene expression omnibus(GEO),network pharmacology,and molecular docking.Methods The Swiss Medical Device Database(SwissTargetPrediction),Pharmacophore Matching and Potential Identification Target Platform(Pharmmapper),Human Genome Database(GeneCards),and Compound Target Prediction Database(TargetNet)were used to search for DMAS related targets.Clinically relevant gene analysis was performed using GEO database and weighted gene co-expression network analysis(WGCNA),and the intersection of the two results with the CRC search results in GeneCards database was taken.By utilizing the protein-protein interaction network analysis database(STRING)and Cytoscape software,a protein-protein interaction(PPI)network was created,and key core targets were screened using the Centiscape plugin.To further validate the reliability of these core targets,detailed analysis was conducted using receiver operating characteristic(ROC)curves and they were imported into the Metascape database for Kyoto encyclopedia of genes and genomes(KEGG)pathway and gene ontology(GO)functional enrichment analysis.Finally,AutoDockTools and Pymol software were used to validate and visualize the molecular docking between DMAS and core target proteins.Results A total of 355 DMAS targets were obtained through the database,and 5200 CRC clinical module genes were obtained through WGCNA.Combined with the GeneCards database,totally of 99 DMAS and CRC cross targets were obtained.15 core targets were identified through PPI network analysis.By analyzing the ROC curve,it was determined that serine/threonine kinase(AKT1),protein P53(TP53),β-catenin(CTNNB1),recombinant heat shock protein 90 kDa alpha B1(HSP90AB1),insulin-like growth factor 1(IGF1),tyrosine kinase receptor 2(ERBB2),phosphatase and tensin homolog deleted on chromosome ten(PTEN),cyclin-dependent kinase 2(CDK2),Kirsten rat sarcoma viral oncogene(KRAS),pepsinogen Ⅰ/Ⅱ ratio(PGR),peroxisome proliferator-activated receptor gamma(PPARG),mothers against decapentaplegic homolog 4(SMAD4),cell cycle regulatory protein kinase 4(CDK4),proto-oncogene PIK3CA,and caspase-9(CASP9)were key targets regulated by DMAS for CRC.KEGG and GO enrichment analysis showed that these targets were mainly concentrated in phosphatidylinositol 3-kinase-protein kinase B(PI3K-Akt)signaling pathways.It was further indicated that by the molecular docking results,DMAS could effectively bind to 15 key targets,forming stable protein ligand complexes.Conclusion This study not only reveals the key targets and molecular mechanisms of anti-CRC of DMAS,but also provides a solid theoretical basis for further exploration of the pharmacological mechanisms of anti-CRC of DMAS in the future.
林晶;江道宏;高献明;许璐;谢芊芊
福建中医药大学附属第二人民医院肛肠科,福建 福州 350000福建省医学科学研究院,福建 福州 350001福建中医药大学附属第二人民医院肛肠科,福建 福州 350000福建中医药大学附属第二人民医院肛肠科,福建 福州 350000福建中医药大学附属第二人民医院肛肠科,福建 福州 350000
医药卫生
紫草β,β-二甲基丙烯酰阿卡宁结直肠癌网络药理学生物信息学
Arnebiae Radixβ,β-dimethylacryloyl alkanninColorectal cancerNetwork pharmacologyBioinformatics
《中国医药科学》 2025 (8)
9-15,43,8
福建省中医药重点学科建设项目(闽卫中医函[2024]363号).
评论